SteadyMed Drug Co. Raises $30M

April 23, 2017 |  SteadyMed Therapeutics, an Israeli medical company, raised $30 million in a private placement led by Adage Capital Management, OrbiMed, Deerfield Management and Kingdon Capital Management. SteadyMed  develops drug product candidates to treat orphan and high-value diseases with unmet delivery needs. The company was founded in 2005 in the Zisapel family’s RAD Biomed incubator. Headquartered in San Ramon, California, much of the company’s development is carried out in its Rehovot offices.  In 2015, the company raised $40 million on Nasdaq and last year raised $32 million in a private placement.